NCT02872857

Subarachnoid Hemorrhage Recovery And Galantamine

A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

Conditions

• Subarachnoid Hemorrhage

Interventions

Type	Name	Description
DRUG	Placebo	Placebo will match drug capsules.
DRUG	8mg galantamine twice daily	Drug will be administered within 36 hours of hospitalization and continued for 90 days.
DRUG	12mg galantamine twice daily	Drug will be administered within 36 hours of hospitalization and continued for 90 days.

Timeline

• Start date: 2016-09-01
• Primary completion: 2019-07-20
• Completion: 2019-07-20
• First posted: 2016-08-19
• Last updated: 2021-10-08
• Results posted: 2021-10-08

Locations

2 sites across 1 country: United States